Spero Therapeutics (NASDAQ:SPRO) Stock Price Passes Above Two Hundred Day Moving Average of $1.31

Spero Therapeutics, Inc. (NASDAQ:SPROGet Free Report) shares crossed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $1.31 and traded as high as $1.40. Spero Therapeutics shares last traded at $1.37, with a volume of 64,749 shares traded.

Analysts Set New Price Targets

A number of analysts have recently commented on the company. HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Spero Therapeutics in a research report on Tuesday, November 14th. Cantor Fitzgerald reissued an “overweight” rating on shares of Spero Therapeutics in a report on Monday, December 18th.

Check Out Our Latest Research Report on SPRO

Spero Therapeutics Stock Up 1.5 %

The stock has a fifty day moving average of $1.42 and a 200-day moving average of $1.31. The stock has a market cap of $72.61 million, a PE ratio of 137.00 and a beta of 0.55.

Spero Therapeutics (NASDAQ:SPROGet Free Report) last released its quarterly earnings results on Monday, November 13th. The company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.17. Spero Therapeutics had a positive return on equity of 4.14% and a negative net margin of 2.08%. The firm had revenue of $25.47 million for the quarter, compared to analyst estimates of $2.40 million. Equities research analysts forecast that Spero Therapeutics, Inc. will post -0.5 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Spero Therapeutics

A number of institutional investors have recently added to or reduced their stakes in the business. Anson Funds Management LP boosted its holdings in Spero Therapeutics by 3.0% in the 2nd quarter. Anson Funds Management LP now owns 3,444,862 shares of the company’s stock valued at $4,995,000 after purchasing an additional 100,000 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Spero Therapeutics by 2.0% during the 3rd quarter. Vanguard Group Inc. now owns 1,557,596 shares of the company’s stock worth $1,885,000 after acquiring an additional 31,122 shares in the last quarter. Renaissance Technologies LLC boosted its stake in shares of Spero Therapeutics by 760.7% during the 2nd quarter. Renaissance Technologies LLC now owns 939,017 shares of the company’s stock worth $696,000 after acquiring an additional 829,917 shares in the last quarter. Millennium Management LLC boosted its stake in shares of Spero Therapeutics by 27.3% during the 4th quarter. Millennium Management LLC now owns 876,398 shares of the company’s stock worth $1,516,000 after acquiring an additional 188,002 shares in the last quarter. Finally, BlackRock Inc. boosted its stake in shares of Spero Therapeutics by 6.9% during the 2nd quarter. BlackRock Inc. now owns 523,804 shares of the company’s stock worth $760,000 after acquiring an additional 33,991 shares in the last quarter. Hedge funds and other institutional investors own 27.25% of the company’s stock.

Spero Therapeutics Company Profile

(Get Free Report)

Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, a direct acting IV-administered agent to treat MDR Gram-negative bacterial infections in the hospital; and SPR720, a novel oral antibiotic for the treatment of non-tuberculous mycobacterial pulmonary disease.

See Also

Receive News & Ratings for Spero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.